RT Journal Article
T1 Public Cord Blood Banks as a source of starting material for clinical grade HLA-homozygous induced pluripotent stem cells.
A1 Álvarez-Palomo, Belén
A1 Veiga, Anna
A1 Raya, Angel
A1 Codinach, Margarita
A1 Torrents, Silvia
A1 Ponce Verdugo, Laura
A1 Rodriguez-Aierbe, Clara
A1 Cuellar, Leopoldo
A1 Alenda, Raquel
A1 Arbona, Cristina
A1 Hernández-Maraver, Dolores
A1 Fusté, Cristina
A1 Querol, Sergi
K1 Cord blood
K1 Cord blood banks
K1 GMP manufacturing
K1 HLA matching
K1 Hematopoietic progenitor cells
K1 Induced pluripotent stem cells
AB The increasing number of clinical trials for induced pluripotent stem cell (iPSC)-derived cell therapy products makes the production on clinical grade iPSC more and more relevant and necessary. Cord blood banks are an ideal source of young, HLA-typed and virus screened starting material to produce HLA-homozygous iPSC lines for wide immune-compatibility allogenic cell therapy approaches. The production of such clinical grade iPSC lines (haplolines) involves particular attention to all steps since donor informed consent, cell procurement and a GMP-compliant cell isolation process. Homozygous cord blood units were identified and quality verified before recontacting donors for informed consent. CD34+ cells were purified from the mononuclear fraction isolated in a cell processor, by magnetic microbeads labelling and separation columns. We obtained a median recovery of 20.0% of the collected pre-freezing CD34+, with a final product median viability of 99.1% and median purity of 83.5% of the post-thawed purified CD34+ population. Here we describe our own experience, from unit selection and donor reconsenting, in generating a CD34+ cell product as a starting material to produce HLA-homozygous iPSC following a cost-effective and clinical grade-compliant procedure. These CD34+ cells are the basis for the Spanish bank of haplolines envisioned to serve as a source of cell products for clinical research and therapy.
YR 2022
FD 2022-08-12
LK http://hdl.handle.net/10668/20362
UL http://hdl.handle.net/10668/20362
LA en
DS RISalud
RD Apr 8, 2025